Research programme: antibacterials - Arpida

Drug Profile

Research programme: antibacterials - Arpida

Alternative Names: Clostridium difficile infection therapies - Arpida; AR 2474; High affinity ligands for bacterial infections - Arpida; MRSA skin infection therapies - Arpida; Topical antibacterials - Arpida

Latest Information Update: 22 Feb 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arpida
  • Developer Evolva Holding SA
  • Class Carbanilides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bacterial infections; Clostridium-difficile-infections; Skin and soft tissue infections

Most Recent Events

  • 14 Dec 2009 Evolva SA has merged with Arpida to form Evolva Holding SA
  • 25 Feb 2009 Suspended - Preclinical for Bacterial infections in European Union (Topical)
  • 25 Feb 2009 Suspended - Preclinical for Clostridium difficile infections in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top